Aveo Pharmaceuticals hired Michael Bailey as chief commercial officer, a new position. Bailey joins from Synta Pharmaceuticals, where he has been chief commercial officer since 2008. Prior to Synta, he worked for ImClone, where he led the global launch of targeted cancer therapy Erbitux as head of the biotech's worldwide commercialization organization. Aveo is preparing to ramp up regulatory and commercial planning activities for tivozanib, a triple VEGF inhibitor in Phase III clinical trials for renal cancer.
Biotechnology company Ensemble Therapeutics hired Ted Hibben as SVP for corporate development. Prior to joining Ensemble, Hibben worked as the chief business officer of Cequent Pharmaceuticals and before Cequent he was VP of business development and alliance management at Coley Pharmaceutical Group.